Targeted hepatitis C screening among ex-injection drug users in the community

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 1, 2014, Pages 116-120

  Wong, Vincent Wai Sun ^a   Wong, Grace Lai Hung ^a   Chim, Angel Mei Ling ^a   Cheng, Tsz Fai ^a   Cheung, Shirley Wing Yan ^a   Lai, Carol Man Sze ^a   Szeto, Kylie Joan Yi ^a   Tsang, Sharon ^a   Wu, Stephen Ho Chun ^a   Yan, Kenneth Kar Lung ^b   Hui, Alex Yui ^b   Yiu, Desmond Chi Him ^b   Wu, Brian Bing Ying ^b   Cheung, David ^b   Chung, Cedric Sze Lai ^b   Lai, Camey Wai Man ^a   Chan, Henry Lik Yuen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Private gastroenterologists ^*  (Hong Kong)

Author keywords

Elasticity; Interferons; Liver cirrhosis; Opioid related disorders; Patient compliance

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DIAGNOSTIC EQUIPMENT; DISEASE SEVERITY; DRUG ABUSE; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C RAPID TEST; HEPATITIS C VIRUS; HUMAN; INJECTION DRUG USER; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; POINT OF CARE TESTING; PRIORITY JOURNAL; SCREENING; TREATMENT RESPONSE;

ELASTICITY; INTERFERONS; LIVER CIRRHOSIS; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE;

ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; COMMUNITY HEALTH SERVICES; COMMUNITY NETWORKS; DRUG USERS; ELASTICITY IMAGING TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HONG KONG; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; POINT-OF-CARE SYSTEMS; RNA, VIRAL; SEVERITY OF ILLNESS INDEX;

EID: 84897583623     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12355     Document Type: Article

References (31)

1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 2012; 156: 271-278.
2. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 2013; 368: 1907-1917.
3. Mallet V, Gilgenkrantz H, Serpaggi J etal. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 2008; 149: 399-403.
4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann. Intern. Med. 2013; 158: 329-337.
5. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N. Engl. J. Med. 2013; 368: 1859-1861.
6. Nelson PK, Mathers BM, Cowie B etal. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583.
7. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-193.
8. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin. Infect. Dis. 2005; 40 (Suppl. 5): S336-338.
9. Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME. Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia. J. Gastroenterol. Hepatol. 2013; 28: 707-716.
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
11. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245-264.
12. Strathdee SA, Palepu A, Cornelisse PG etal. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-549.
13. Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010; 376: 1441-1442.
14. Wong GL, Wong VW, Choi PC etal. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin. Gastroenterol. Hepatol. 2008; 6: 1027-1035.
15. Fraquelli M, Rigamonti C, Casazza G etal. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973.
16. Narcotics Division, Security Bureau, the Government of the Hong Kong Special Administrative Region. Drug Abuse Trends for 2002-2011. Cited 29 May 2013. Available from URL: http://www.nd.gov.hk/en/crda_61st_report.htm.
17. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann. Intern. Med. 2012; 157: 817-822.
18. Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am. J. Gastroenterol. 2013; 108: 981-989.
19. Spaulding AC, Weinbaum CM, Lau DT etal. A framework for management of hepatitis C in prisons. Ann. Intern. Med. 2006; 144: 762-769.
20. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann. Intern. Med. 2012; 157: 558-566.
21. Yan KK, Wong GL, Wong VW, Chan HL. Rate and factors affecting treatment uptake of patients with chronic hepatitis C in a tertiary referral hospital. Dig. Dis. Sci. 2010; 55: 3541-3547.
22. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
23. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
24. Sherman KE, Flamm SL, Afdhal NH etal. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365: 1014-1024.
25. McHutchison JG, Manns MP, Muir AJ etal. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010; 362: 1292-1303.
26. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-1217.
27. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-2428.
28. Lok AS, Gardiner DF, Lawitz E etal. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 2012; 366: 216-224.
29. Gane EJ, Stedman CA, Hyland RH etal. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013; 368: 34-44.
30. Jacobson IM, Gordon SC, Kowdley KV etal. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013; 368: 1867-1877.
31. Lawitz E, Mangia A, Wyles D etal. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013; 368: 1878-1887.